Sumitomo Pharma Co

Company snapshot

This is the official company page of Sumitomo Pharma Co., Ltd. The Sumitomo Pharma Group defines its Mission as “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.” The Sumitomo Pharma Group aims to fulfill this Mission by delivering innovative, effective pharmaceutic

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sumitomo Pharma Co. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Sumitomo Pharma Co.

1. Jun 5, 2026 Clinical update

   BBI608 — Phase 2

2. May 26, 2026 Clinical update

   Lurasidone — Phase 3

3. May 26, 2026 Clinical update

   Napabucasin — Phase 3

4. May 26, 2026 Clinical update

   Placebo — Phase 3

View all clinical trial activity →

• What is Sumitomo Pharma Co?

  Sumitomo Pharma (Suzhou) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Malignant Pleural Mesothelioma, Bipolar I Depression, Carcinoma, Pancreatic Ductal, Bipolar Depression. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), an

• Is Sumitomo Pharma Co publicly traded?

  Sumitomo Pharma Co appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sumitomo Pharma Co develop or market?

  We link 3 drug profile(s) where Sumitomo Pharma Co is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sumitomo-pharma-suzhou-co#company-drugs.

• What are the latest developments for Sumitomo Pharma Co?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sumitomo Pharma Co focus on?

  Sumitomo Pharma Co focuses on Malignant Pleural Mesothelioma, Bipolar I Depression, Carcinoma, Pancreatic Ductal based on our analysis of their pipeline programs and drug development activities.